ImmunityBio (IBRX) Share-based Compensation (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Share-based Compensation data on file, last reported at $8.2 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.2 million, down 14.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.4 million (down 0.73% YoY), and the FY2025 annual result was $36.8 million, up 6.9% from the prior year.
• Share-based Compensation slipped to $8.2 million in Q1 2026 per IBRX's latest filing, from $8.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $14.4 million in Q3 2023 and troughed at $7.5 million in Q3 2024.
• A 5-year average of $9.9 million and a median of $9.6 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 36.62% in 2023, then sank 48.17% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $9.4 million in 2022, then jumped by 36.62% to $12.8 million in 2023, then retreated by 29.25% to $9.0 million in 2024, then slipped by 3.23% to $8.7 million in 2025, then retreated by 6.6% to $8.2 million in 2026.
• Business Quant data shows IBRX's Share-based Compensation at $8.2 million in Q1 2026, $8.7 million in Q4 2025, and $8.9 million in Q3 2025.